title: Assessing the risks for poliovirus outbreaks in polio-free countries--Africa, 2012-2013.
abstract: In 2012, the World Health Assembly of the World Health Organization (WHO) declared the completion of polio eradication a programmatic emergency. Indigenous wild poliovirus (WPV) transmission remains uninterrupted in Nigeria (in the WHO African Region [AFR]) and in Afghanistan and Pakistan (in the WHO Eastern Mediterranean Region [EMR]). In the WHO AFR, multiple WPV outbreaks have occurred since 2003 after importation of indigenous West African WPV into 21 previously polio-free countries in a "WPV importation belt"* that extends across the continent. The Global Polio Eradication Initiative (GPEI) and WHO regional offices have used indicators of population immunity, surveillance quality, and other factors (e.g., high-risk subpopulations and proximity to WPV-affected countries) to assess the risk for outbreaks in polio-free countries and guide the implementation of risk mitigation measures to limit poliovirus transmission after WPV importation and prevent the emergence of circulating vaccine-derived poliovirus (cVDPV). Despite risk mitigation efforts, a polio outbreak, first confirmed in May 2013, is ongoing; as of September 10, a total of 178 WPV type 1 (WPV1) cases have been reported in Somalia† (163 cases), Kenya (14 cases) and Ethiopia (1 case), after importation of WPV1 of West African origin. This report summarizes steps taken by the GPEI to assess and mitigate the risks for outbreaks after WPV importation or the emergence of cVDPV in polio-free countries within the WHO AFR's "WPV importation belt." All countries will continue to have some level of risk for WPV outbreaks as long as endemic circulation continues in Afghanistan, Nigeria, and Pakistan.
mesh_terms: D000349:Africa / Q000453:epidemiology; D004196:Disease Outbreaks / Q000517:prevention & control*; D006801:Humans; D032541:Mass Vaccination; D011051:Poliomyelitis / Q000453:epidemiology* / Q000517:prevention & control; D023321:Poliovirus Vaccines / Q000008:administration & dosage; D011159:Population Surveillance; D018570:Risk Assessment
chemical_list: D023321:Poliovirus Vaccines
references.citation: MMWR Morb Mortal Wkly Rep. 2013 May 3;62(17):335-8
references.pmid: 23636027
references.citation: Risk Anal. 2006 Dec;26(6):1541-56
references.pmid: 17184396
references.citation: MMWR Morb Mortal Wkly Rep. 2013 Jun 14;62(23):484
references.pmid: 23760191
references.citation: MMWR Morb Mortal Wkly Rep. 2012 Nov 9;61(44):899-904
references.pmid: 23134973
references.citation: Risk Anal. 2013 Apr;33(4):664-79
references.pmid: 23520991
references.citation: MMWR Morb Mortal Wkly Rep. 2013 Apr 12;62(14):270-4
references.pmid: 23575241
references.citation: MMWR Morb Mortal Wkly Rep. 2010 Nov 5;59(43):1393-9
references.pmid: 21048560
references.citation: MMWR Morb Mortal Wkly Rep. 2009 Apr 17;58(14):357-62
references.pmid: 19373195